Trial intelligence / Profile preview

INS068 Injection vs Insulin Degludec in Type 2 Diabetes Mellitus

CTR20210081Phase 2Completed

Sponsor
Hengrui Therapeutics
Start
Jan 2021
Modality
Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Peptides
Countries
1
01

Overview

A Phase 2 trial of insulin sudelidec in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Jan 2021; status: completed.

02

Drugs

insulin sudelidec
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on CTR20210081.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20210081.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call